Navigation Links
Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
Date:12/9/2010

DALLAS and NEW YORK, Dec. 9, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has made significant progress in obtaining MuGard reimbursements from various third-party payer networks.  Some of the national insurance reimbursements included several state plans from Blue Cross Blue Shield, Health Net, Caremark, Well Point Next Rx, Harvard Pilgrim and Medicaid.

"Receiving these reimbursements affirms that national payers understand the critical role MuGard plays in the management of oral mucositis and serves as strong validation of the clinical and pharmacoeconomic viability MuGard offers," said Jeff Davis, President and CEO, Access Pharmaceuticals. He continued, "Our effort to land additional reimbursements is ongoing as it provides an incentive for clinics and hospitals to more quickly integrate the MuGard into their treatment protocols for cancer patients."

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  While you may be familiar with watching a film or ... also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized ... innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... May 3, 2016 According to ... Share, Development, Growth and Demand Forecast to 2022 - ... Strength (High Field, Very High Field, Low to Mid ... and Neck, Spine, Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, ... resonance imaging (MRI) market was valued at $5,351.7 million ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Over 40 athletic trainer’s (ATs) and athletic ... for the annual “Hike to Harrisburg” advocacy day. The annual lobbying effort is ... lobby Group. The goal for the day was to educate the elected legislators ...
(Date:5/4/2016)... ... May 04, 2016 , ... Vasont Systems, a ... Integrator (VUI) extension supports the latest release of Adobe FrameMaker, Release 2015. The ... the process of creating, editing and storing XML. , The VUI ...
(Date:5/3/2016)... , ... May 04, 2016 , ... ... cancer. That message is reaching the global health community through expanding activities that ... burden of cancer in the resource-limited countries. , In support of ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... Journal, patients report dissatisfaction with numerous issues related to medical care in the ... billing, and poor bedside manner from hospital staff. Commenting on this article, the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Sue Desmond-Hellmann, chief executive ... 2016 to stretch the limits of human possibility in her keynote address at Georgia ... the Georgia Dome. , Drawing on her rich experience as a scientist, physician and ...
Breaking Medicine News(10 mins):